Aernoud Fiolet

112 Chapter 4 REFERENCES 1. K. Ueki, T. Sasako, Y. Okazaki, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label randomised controlled trial Lancet Diabetes Endocrinol, 5 (12) (2017), pp. 951-964 2. C.P. Cannon, M.A. Blazing, R.P. Giugliano, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med, 372 (25) (2015), pp. 2387-2397 3. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. 4. G.G. Schwartz, P.G. Steg, M. Szarek, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med (2018), pp. 1-10 5. D.R. Berlowitz, C.G. Foy, L.E. Kazis, et al. Effect of intensive blood-pressure treatment on patient- reported outcomes. N Engl J Med, 377 (8) (2017), pp. 733-744 6. M.A. Bethel, H.A.W. Neil, S.K. Paul, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 359 (15) (2008), pp. 1577-15897. 7. J.W. Eikelboom, S.J. Connolly, J. Bosch, et al.Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med, 377 (14) (2017), pp. 1319-1330 8. N. Niyonzima, B. Halvorsen, B. Sporsheim, et al. Complement activation by cholesterol crystals triggers a subsequent cytokine response. Mol Immunol, 84 (2017), pp. 43-50. 9. P. Duewell, H. Kono, K.J. Rayner, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature, 464 (7293) (2010), pp. 1357-1361 10. S.R. Mulay, H.-J. Anders. Crystallopathies. N Engl J Med, 374 (25) (2016), pp. 2465-2476 11. K. Vaidya, C. Arnott, G.J. Martínez, et al. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: A CT coronary angiography study. JACC Cardiovasc Imaging, 11 (2) (2018), pp. 305-316 12. P.M. Ridker, B.M. Everett, T. Thuren, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med, 377 (12) (2017), pp. 1119-1131 13. B.N. Cronstein, Y. Molad, J. Reibman, et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest, 96 (2) (1995), pp. 994-1002 14. P. Libby. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med, 368 (21) (2013), pp. 2004-2013 15. P. Libby, I. Tabas, G. Fredman, et al. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res, 114 (12) (2014), pp. 1867-1879 16. N. Dalbeth, T.J. Lauterio, H.R. Wolfe. Mechanism of action of colchicine in the treatment of gout. Clin Ther, 36 (10) (2014), pp. 1465-1479 17. Y.Y. Leung, L.L. Yao Hui, V.B. Kraus. Colchicine-update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum, 45 (3) (2015), pp. 341-350 18. C.M. Artlett. Inflammasomes in wound healing and fibrosis. J Pathol, 229 (2) (2013), pp. 157-167 19. B. Shah, N. Allen, B. Harchandani, et al. Effect of colchicine on platelet-platelet and platelet- leukocyte interactions: a pilot study in healthy subjects. Inflammation, 39 (1) (2016), pp. 182-189 20. D. Zemer, M. Revach, M. Pras, et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med, 291 (18) (1974), pp. 932-934. 21. L.P.H. Yang. Oral colchicine (Colcrys®). Drugs, 70 (12) (2010), pp. 1603-1613, 22.